ZA201505025B - 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2 inhibitors - Google Patents
2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2 inhibitorsInfo
- Publication number
- ZA201505025B ZA201505025B ZA2015/05025A ZA201505025A ZA201505025B ZA 201505025 B ZA201505025 B ZA 201505025B ZA 2015/05025 A ZA2015/05025 A ZA 2015/05025A ZA 201505025 A ZA201505025 A ZA 201505025A ZA 201505025 B ZA201505025 B ZA 201505025B
- Authority
- ZA
- South Africa
- Prior art keywords
- dihydroimidazol
- pyrimidin
- associated phospholipase
- pla2 inhibitors
- based lipoprotein
- Prior art date
Links
- 102000016752 1-Alkyl-2-acetylglycerophosphocholine Esterase Human genes 0.000 title 1
- YHPVIBUEXBEHPV-UHFFFAOYSA-N 2,6-dihydro-1h-pyrimidin-5-one Chemical compound O=C1CNCN=C1 YHPVIBUEXBEHPV-UHFFFAOYSA-N 0.000 title 1
- 108010024976 Asparaginase Proteins 0.000 title 1
- 239000003358 phospholipase A2 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013070976 | 2013-01-25 | ||
| CN2013001556 | 2013-12-12 | ||
| PCT/EP2014/051286 WO2014114694A1 (en) | 2013-01-25 | 2014-01-23 | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201505025B true ZA201505025B (en) | 2017-08-30 |
Family
ID=50002724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2015/05025A ZA201505025B (en) | 2013-01-25 | 2015-07-13 | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2 inhibitors |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9708330B2 (OSRAM) |
| EP (1) | EP2948452B1 (OSRAM) |
| JP (1) | JP6306053B2 (OSRAM) |
| KR (1) | KR20150108897A (OSRAM) |
| CN (1) | CN105008368B (OSRAM) |
| AU (1) | AU2014209949B2 (OSRAM) |
| BR (1) | BR112015017759B1 (OSRAM) |
| CA (1) | CA2899091A1 (OSRAM) |
| CL (1) | CL2015002060A1 (OSRAM) |
| CR (1) | CR20150390A (OSRAM) |
| EA (1) | EA025885B1 (OSRAM) |
| ES (1) | ES2642762T3 (OSRAM) |
| HK (1) | HK1216425A1 (OSRAM) |
| IL (1) | IL240046A0 (OSRAM) |
| MA (1) | MA38284B1 (OSRAM) |
| MX (1) | MX2015009633A (OSRAM) |
| PE (1) | PE20151251A1 (OSRAM) |
| PH (1) | PH12015501586A1 (OSRAM) |
| SG (1) | SG11201505520WA (OSRAM) |
| TW (1) | TW201443054A (OSRAM) |
| UY (1) | UY35276A (OSRAM) |
| WO (1) | WO2014114694A1 (OSRAM) |
| ZA (1) | ZA201505025B (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015009633A (es) | 2013-01-25 | 2015-11-30 | Glaxosmithkline Ip Dev Ltd | Inhibidores de fosfolipasa a2 asociada con lipoproteinas basados en 2,3-dihidroimidazol[1,2-c] pirimidin-5(1h)-ona. |
| WO2016012917A1 (en) * | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| CN106536525B (zh) * | 2014-07-22 | 2019-05-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 化合物 |
| WO2016012916A1 (en) * | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| CN104892459A (zh) * | 2015-06-16 | 2015-09-09 | 苏州明锐医药科技有限公司 | 利奥西呱中间体及其制备方法 |
| CN112574221B (zh) * | 2019-09-30 | 2022-03-04 | 上海纽思克生物科技有限公司 | 四环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| CN112778331B (zh) | 2019-11-09 | 2022-07-05 | 上海赛默罗生物科技有限公司 | 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| CN111533699B (zh) * | 2020-05-27 | 2023-12-01 | 龙曦宁（上海）医药科技有限公司 | 一种2-（三氟甲基）嘧啶-5-醇的合成方法 |
| CN113861220B (zh) * | 2020-06-30 | 2023-06-16 | 上海纽思克生物科技有限公司 | 三环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| CN113912622B (zh) * | 2020-07-10 | 2023-12-01 | 上海纽思克生物科技有限公司 | 三环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| CN114057740B (zh) * | 2021-12-15 | 2024-04-02 | 上海赛默罗生物科技有限公司 | 螺环嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| US20250154153A1 (en) * | 2022-08-04 | 2025-05-15 | 4B Technologies (Beijing) Co., Limited | Dihydroimidazo-pyrimidinone compounds as lp-pla2 inhibitors and use thereof |
| CN116925023B (zh) * | 2023-07-18 | 2025-11-21 | 江苏桐孚高新材料有限公司 | 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993018035A1 (en) | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| GB9421816D0 (en) | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
| AR002012A1 (es) | 1994-12-22 | 1998-01-07 | Smithkline Beecham Plc | Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto. |
| CH690264A5 (fr) | 1995-06-30 | 2000-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques. |
| KR19990028630A (ko) | 1995-07-01 | 1999-04-15 | 데이비드 로버츠 | 아테롬성 동맥경화증을 치료하기 위한 아제티디논 유도체 |
| CA2233300A1 (en) | 1995-09-29 | 1997-04-10 | Christopher Donald Southan | A paf-acetylhydrolase and use in therapy |
| JP2000505063A (ja) | 1995-12-08 | 2000-04-25 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アテローム性動脈硬化症の治療のためのアゼチジノン化合物 |
| JP2000502079A (ja) | 1995-12-08 | 2000-02-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体 |
| GB9608649D0 (en) | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
| AU2698697A (en) | 1996-04-26 | 1997-11-19 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis |
| GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| JP2001522844A (ja) | 1997-11-06 | 2001-11-20 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ピリミジノン化合物およびそれを含有する医薬組成物 |
| WO2000010980A1 (en) | 1998-08-21 | 2000-03-02 | Smithkline Beecham Plc | Pyrimidinone derivatives for the treatment of atherosclerosis |
| GB9910079D0 (en) | 1999-05-01 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
| PT1175408E (pt) | 1999-05-01 | 2005-04-29 | Smithkline Beecham Plc | Derivados sulfonamida |
| GB9910378D0 (en) | 1999-05-05 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
| JP3757703B2 (ja) | 1999-09-22 | 2006-03-22 | 凸版印刷株式会社 | 再封可能な開口維持部材付パウチ |
| BRPI0108396B1 (pt) | 2000-02-16 | 2015-05-19 | Smithkline Beecham Plc | Derivados de pirimidina-4-ona como inibidores de ldl-pla2 |
| GB0024807D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| GB0119795D0 (en) | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel process |
| GB0119793D0 (en) | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
| GB0127140D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127141D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham Plc | Novel compounds |
| GB0127143D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127139D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0208280D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| GB0208279D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| EP1644353A1 (de) | 2003-07-02 | 2006-04-12 | Bayer HealthCare AG | Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten |
| DE102004061009A1 (de) | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | Substituierte 1,2,4-Triazin-5(2H)-one |
| DE102004061008A1 (de) | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one |
| US7705005B2 (en) | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
| EP2083625A4 (en) | 2006-10-13 | 2011-10-19 | Glaxo Group Ltd | BICYCLIC HETOROAROMATIC COMPOUNDS |
| US20080090851A1 (en) | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
| US20080090852A1 (en) | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
| US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| JP5437996B2 (ja) | 2007-05-11 | 2014-03-12 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 皮膚潰瘍の治療方法 |
| US20080279846A1 (en) | 2007-05-11 | 2008-11-13 | Thomas Jefferson University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| JP2011088847A (ja) | 2009-10-21 | 2011-05-06 | Takeda Chem Ind Ltd | 三環性化合物およびその用途 |
| US8871928B2 (en) * | 2010-09-20 | 2014-10-28 | Glaxo Group Limited | Tricyclic compounds, preparation methods, and their uses |
| EP2649050A4 (en) * | 2010-12-06 | 2014-04-23 | Glaxo Group Ltd | LINKS |
| ES2847883T3 (es) | 2010-12-17 | 2021-08-04 | Glaxo Group Ltd | Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares |
| CN103827116B (zh) * | 2011-07-27 | 2016-08-31 | 葛兰素集团有限公司 | 用作LP-PLA2抑制剂的2,3-二氢咪唑并[1,2-c]嘧啶-5(1H)-酮化合物 |
| JP2014521611A (ja) * | 2011-07-27 | 2014-08-28 | グラクソ グループ リミテッド | Ｌｐ−ＰＬＡ２阻害剤としての２，３−ジヒドロイミダゾ［１，２−ｃ］ピリミジン−５（１Ｈ）−オン化合物の使用 |
| MX2015009633A (es) | 2013-01-25 | 2015-11-30 | Glaxosmithkline Ip Dev Ltd | Inhibidores de fosfolipasa a2 asociada con lipoproteinas basados en 2,3-dihidroimidazol[1,2-c] pirimidin-5(1h)-ona. |
-
2014
- 2014-01-23 MX MX2015009633A patent/MX2015009633A/es unknown
- 2014-01-23 US US14/761,636 patent/US9708330B2/en not_active Expired - Fee Related
- 2014-01-23 MA MA38284A patent/MA38284B1/fr unknown
- 2014-01-23 BR BR112015017759-0A patent/BR112015017759B1/pt not_active IP Right Cessation
- 2014-01-23 PE PE2015001537A patent/PE20151251A1/es not_active Application Discontinuation
- 2014-01-23 AU AU2014209949A patent/AU2014209949B2/en not_active Ceased
- 2014-01-23 WO PCT/EP2014/051286 patent/WO2014114694A1/en not_active Ceased
- 2014-01-23 CN CN201480013675.8A patent/CN105008368B/zh not_active Expired - Fee Related
- 2014-01-23 CA CA2899091A patent/CA2899091A1/en not_active Abandoned
- 2014-01-23 ES ES14701355.1T patent/ES2642762T3/es active Active
- 2014-01-23 UY UY0001035276A patent/UY35276A/es not_active Application Discontinuation
- 2014-01-23 EP EP14701355.1A patent/EP2948452B1/en active Active
- 2014-01-23 SG SG11201505520WA patent/SG11201505520WA/en unknown
- 2014-01-23 JP JP2015554138A patent/JP6306053B2/ja not_active Expired - Fee Related
- 2014-01-23 KR KR1020157022396A patent/KR20150108897A/ko not_active Ceased
- 2014-01-23 EA EA201591379A patent/EA025885B1/ru not_active IP Right Cessation
- 2014-01-23 HK HK16104389.3A patent/HK1216425A1/zh unknown
- 2014-01-23 TW TW103102388A patent/TW201443054A/zh unknown
-
2015
- 2015-07-13 ZA ZA2015/05025A patent/ZA201505025B/en unknown
- 2015-07-20 PH PH12015501586A patent/PH12015501586A1/en unknown
- 2015-07-20 IL IL240046A patent/IL240046A0/en unknown
- 2015-07-23 CL CL2015002060A patent/CL2015002060A1/es unknown
- 2015-07-24 CR CR20150390A patent/CR20150390A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1216425A1 (zh) | 2016-11-11 |
| PE20151251A1 (es) | 2015-09-10 |
| CN105008368A (zh) | 2015-10-28 |
| US20150361082A1 (en) | 2015-12-17 |
| CN105008368B (zh) | 2017-02-01 |
| PH12015501586A1 (en) | 2015-10-05 |
| ES2642762T3 (es) | 2017-11-20 |
| EA025885B1 (ru) | 2017-02-28 |
| MA38284A1 (fr) | 2017-12-29 |
| EP2948452A1 (en) | 2015-12-02 |
| IL240046A0 (en) | 2015-08-31 |
| UY35276A (es) | 2014-08-29 |
| KR20150108897A (ko) | 2015-09-30 |
| EP2948452B1 (en) | 2017-08-09 |
| SG11201505520WA (en) | 2015-08-28 |
| CR20150390A (es) | 2015-10-19 |
| US9708330B2 (en) | 2017-07-18 |
| MA38284B1 (fr) | 2018-05-31 |
| JP2016505058A (ja) | 2016-02-18 |
| JP6306053B2 (ja) | 2018-04-04 |
| BR112015017759B1 (pt) | 2022-05-24 |
| AU2014209949B2 (en) | 2016-09-08 |
| CA2899091A1 (en) | 2014-07-31 |
| AU2014209949A1 (en) | 2015-07-30 |
| EA201591379A1 (ru) | 2016-01-29 |
| MX2015009633A (es) | 2015-11-30 |
| BR112015017759A2 (pt) | 2017-07-11 |
| WO2014114694A1 (en) | 2014-07-31 |
| CL2015002060A1 (es) | 2015-11-27 |
| TW201443054A (zh) | 2014-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201505025B (en) | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2 inhibitors | |
| IL265253A (en) | Reversible pyrimidine compounds inhibit bmi–1 | |
| IL261282A (en) | Furinone compounds as kinase inhibitors | |
| ZA201601697B (en) | Substituted pyrimidine bmi-1 inhibitors | |
| IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
| EP3016953A4 (en) | Purinone compounds as kinase inhibitors | |
| SG11201600062RA (en) | Pyrimidine derivatives as kinase inhibitors | |
| EP3067356A4 (en) | Pyrrolo pyrimidine derivative | |
| IL243092A0 (en) | New triazolo[d–4,5]pyrimidine histories | |
| AP2015008867A0 (en) | 3,4-dihydroisquinolin-2(1h)-yl compounds | |
| EP3054948A4 (en) | Rapamycin for the treatment of lymphangioleiomyomatosis | |
| ZA201406038B (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| ZA201506327B (en) | Macrocyclic lrrk2 kinase inhibitors | |
| PT2694513E (pt) | Derivados de pirazolopirimidina | |
| EP2929429A4 (en) | BARE CONTROLS FOR DRAWN OBJECTS | |
| IL244817A0 (en) | Transmuted pyrimidine compounds and their use as syk inhibitors | |
| EP2948456A4 (en) | BICYCLIC PYRIMIDONE COMPOUNDS AS LP-PLA2 INHIBITORS | |
| EP2900243A4 (en) | BICYCLIC OXA LACTAM KINASE HEMMER | |
| EP3008202A4 (en) | Methods for detecting the presence of microbes | |
| EP3087060A4 (en) | Pyrimidone carboxamide compounds as pde2 inhibitors | |
| EP3072527A4 (en) | Immunosuppressant | |
| LT2948443T (lt) | Nauji pirimidino dariniai kaip fosfodiesterazės 10 inhibitoriai (pde-10) | |
| HK1224675A1 (en) | Purinone compounds as kinase inhibitors | |
| HK1225374A1 (en) | Syk inhibitors |